Suppression of lung cancer cell proliferation, mediated partially by inhibition of NF-κB, may require high doses of EGCG; however, combined administration of EGCG with, e.g., NF-κB inhibitor may exert significant synergistic effect at relatively low concentrations [223]. The gene discussed is NFKB1; the disease is lung cancer.